European Archives - Page 423 of 1125 - European Medical Journal

Pharma in the UK

In 2021, the UK was named the sixth biggest pharmaceutical market, but it’s facing challenges to further growth. Read to find out more.

Dr Zsuzsanna Devecseri

Access to oncology treatments, diversity and lessons in leadership

The GOLD team are joined by Dr Zsuzsanna Devecseri, Vice President and Head of Global Oncology Medical, Sanofi Genzyme, to discuss her career journey and varied experience within the pharmaceutical industry.

Widal Positivity: Tuberculosis Diagnosis and Fluoroquinolone Resistance

Drug resistance among patients with tuberculosis (TB) is an emergent topic that requires intervention. According to a survey of TB drug resistance in India, resistance to any fluoroquinolones (FQ) reported in cases of multidrug resistance (MDR) to TB was 21.82%.

Advancing diversity in clinical trials

This infographic explores the diversity of patient populations in US clinical trials and the pharmaceutical industry’s efforts to address this and improve outcomes.

Interview: Hannah Gower

Hannah Gower | Cardiology and Internal Medicine Speciality Registrar, Royal Cornwall Hospitals NHS Trust, UK

Rheumatology Through Time

Adam Brown joins Jonathan to discuss teaching in rheumatology and the history of rheumatological conditions. Listen now!

Imaging After Histotripsy: A Non-invasive, Non-thermal Therapy for Cancer

Histotripsy is a non-invasive, non-thermal, and non-ionising focused ultrasound (US) treatment method that destroys tissue through mechanical disruption caused by cavitation. Short-duration (<20 μs) high-pressure US pulses cause the rapid expansion and collapse of endogenous gas bubbles in targeted tissue.

Interview: Juan Gómez Rivas

Juan Gómez Rivas | Urology Consultant, Hospital Clinico San Carlos, Madrid, Spain; Assistant Professor, Universidad Complutense de Madrid, Spain

EMJ Hepatology 11 [Supplement 1] 2023

Cholestatic liver diseases include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and progressive familial intrahepatic cholestasis (PFIC). In all of these conditions, cholestatic itch is a major symptom that can severely and chronically impact a person’s quality of life (QoL).

The New International Wound Infection Institute’s (IWII) Consensus Document: Implementation into Clinical Practice

This webinar discusses the new International Wound Infection Institute’s Consensus Document, which details up-to-date best practice guidelines for wound infection management.